Metastatic Castrate Resistant Prostate Cancer Clinical Trial
Official title:
Detection of ARv7 in the Plasma of Men With Advanced Metastatic Castrate Resistant Prostate Cancer (MCRP)
Demonstrate detection of ARv7 splice variant transcripts from exosomes in the circulation of MCRPC patients pre and post treatment with selective Androgen pathway inhibitors (i.e. abiraterone and enzalutamide)
Primary Objective -Demonstrate detection of ARv7 splice variant transcripts from exosomes in the circulation of MCRPC patients pre and post treatment with selective Androgen pathway inhibitors (i.e. abiraterone and enzalutamide) Secondary and Exploratory Objectives - Correlate ARv7 status with PSA response (>/=50% decline in PSA level from baseline, maintained for >/=4 weeks) at any time after the initiation of therapy. - Comparison of median progression free survival (PFS) and overall survival (OS). - Determine additional molecular lesions in exoRNA and cfDNA in MCRPC patients post-treatment with androgen pathway inhibitors. - Correlate other AR-variants (non ARv7) with clinical outcomes including PSA response. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03761225 -
Masitinib Plus Docetaxel in Metastatic Castration-resistant Prostate Cancer
|
Phase 3 | |
| Recruiting |
NCT04038502 -
Carboplatin or Olaparib for BRcA Deficient Prostate Cancer
|
Phase 2 | |
| Terminated |
NCT03729596 -
MGC018 With or Without MGA012 in Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT03737370 -
Fractionated Docetaxel and Radium 223 in Metastatic Castration-Resistant Prostate Cancer
|
Phase 1 | |
| Terminated |
NCT01732549 -
A Proof of Concept Study of Maintenance Therapy With Tasquinimod in Patients With Metastatic Castrate-resistant Prostate Cancer Who Are Not Progressing After a First Line Docetaxel Based Chemotherapy
|
Phase 2 | |
| Completed |
NCT01090765 -
A Phase I/II Study of TRC105 in Metastatic Castrate Resistant Prostate Cancer (CRPC)
|
Phase 1/Phase 2 |